1 (017 18)
Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 73190-017
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 73190-017). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (017 60)
1 (018 18)
1 (018 60)
1 (019 18)
This is a description of Sacubitril and Valsartan Tablets with NDC73190-019-18 code. The tablets are intended for prescription use only and come in a pack of 180 tablets. The text also mentions a contact phone number starting with 4859520.*
1 (019 60)
This is a description of a medication labeled NDC73190-018-60, containing Sacubitril and Valsartan Tablets. The text also mentions instructions related to the tablets' usage, possibly information related to the correct dosage and administration. It is recommended to refer to the official packaging or medical guidelines for precise details and instructions on usage.*
Chem Structure (Sacubitril And Valsartan Tablets 1)
Figure 7 (Sacubitril And Valsartan Tablets 10)
This text provides information about two clinical trials related to heart failure: PARADIGM-HF and PARAGON-HF. The trials compare sacubitril and valsartan combination versus enalapril and valsartan alone. The evaluation includes parameters like left ventricular ejection fraction at screening.*
Figure 1 (Sacubitril And Valsartan Tablets 2)
This text provides information on the Geometric Mean Ratio and 90% CI for the coadministered drugs listed, showcasing changes relative to the reference drug. It includes drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amiodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil.*
Figure 2 (Sacubitril And Valsartan Tablets 3)
This text provides information on the population description, including details on renal impairment levels (mild, moderate, severe), hepatic impairment levels (mild, moderate), and age range (26-45 years). Additionally, it mentions Geometric Mean Ratio and 90% Confidence Interval, but the specific values are not available.*
Figure 3a (Sacubitril And Valsartan Tablets 4)
This document provides information about the time to the first occurrence of cardiovascular (CV) death or heart failure hospitalizations in the PARADIGM-HF study. The data indicates a statistically significant result with p<0.0001, showing a Hazard Ratio (HR) of 0.80 with a 95% confidence interval of 0.73-0.87. The Kaplan-Meier estimate of the cumulative failure rate over time is also presented. The study compares outcomes between two groups, one receiving Enalapril and the other receiving an unspecified medication. It illustrates different time points and the number of patients at risk at those time intervals.*
Figure 3b (Sacubitril And Valsartan Tablets 5)
Figure 3c (Sacubitril And Valsartan Tablets 6)
This text provides information related to the Time to First Occurrence of Heart Failure Hospitalizations in PARADIGM-HF study. It includes a figure labeled as Figure C and data on hazard ratio, confidence interval, Kaplan-Meier estimate of cumulative failure rate, time since randomization in days, and the number at risk in the study. The text appears to be presenting data for the study's analysis.*
Figure 4 (Sacubitril And Valsartan Tablets 7)
Figure 5 (Sacubitril And Valsartan Tablets 8)
Figure 6 (Sacubitril And Valsartan Tablets 9)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
